AUA2025: PARP-Inhibitor Combination Treatments for the Urologic Care Team

CME Available: https://auau.auanet.org/node/42822

At the conclusion of this CME activity, participants will be able to:

1. Apply the mechanism of action of PARP inhibitors and the rationale for using them in patients with advanced prostate cancer.

2. Recognize the role and importance of genetic testing in patients with mCRPC and the implications of germline mutations on response to therapy.

3. Identify best practices and utilize available guidelines for patients with mCRPC to optimize treatment success and oncologic outcomes.

4. Recognize when to use PARP inhibitors as monotherapy, the rationale and indications for combination therapy, and appropriate treatment sequencing.

5. Successfully counsel patients on the possible adverse events associated with PARP inhibitor therapies alone or in combination.

ACKOWLEDGEMENTS

Support provided by independent educational grants from:

AstraZeneca

Merck & Co., Inc.